Schizophrenia & Psychoses

FDA Approves New Schizophrenia Treatment for Adolescents

FDA Approves New Schizophrenia Treatment for Adolescents

By

The FDA has approved a new treatment for adolescents between the ages of 13 and 17 years who are diagnosed with schizophrenia.

Factors Predicting Favorable Outcomes in First-Episode Psychosis Without Medication

Factors Predicting Favorable Outcomes in First-Episode Psychosis Without Medication

By

Researchers profiled which young people may do well after first-episode psychosis without medication.

Low-Dose Metformin May Reduce Body Weight and BMI in Clozapine-Treated Schizophrenia

Low-Dose Metformin May Reduce Body Weight and BMI in Clozapine-Treated Schizophrenia

By

These study results indicate that early intervention with low doses of metformin in patients with few metabolic abnormalities may be beneficial.

Childhood Trauma, Depression Associated With Impaired Quality of Life in Schizophrenia

Childhood Trauma, Depression Associated With Impaired Quality of Life in Schizophrenia

By

Targeting negative symptoms in patients with schizophrenia may be more effective in improving patients' QoL.

Cardiometabolic Factors in Youth Schizophrenia Treatment

Cardiometabolic Factors in Youth Schizophrenia Treatment

By

Pretreatment cardiometabolic status to be taken into consideration for treatment of first episode psychosis.

Facial Affect Recognition Training Improves Social Outcomes in Psychosis

Facial Affect Recognition Training Improves Social Outcomes in Psychosis

By

Inability to interpret facial expressions may exacerbate psychotic symptoms, either indirectly via social defeat or directly by creating confusing interpersonal experiences.

Pediatric Patients Should Undergo Electrocardiogram Assessment Before Antipsychotic Treatment

Pediatric Patients Should Undergo Electrocardiogram Assessment Before Antipsychotic Treatment

By

Cardiac safety is integral to child and adolescent antipsychotic therapy.

VIDEO: Schizophrenia Linked to Type 2 Diabetes

VIDEO: Schizophrenia Linked to Type 2 Diabetes

Patients with early schizophrenia may have already started down the road to diabetes, even prior to actual diagnosis.

Antipsychotic Switching in Schizophrenia: Immediate vs Gradual Discontinuation

Antipsychotic Switching in Schizophrenia: Immediate vs Gradual Discontinuation

By

Both immediate and gradual discontinuation of the current antipsychotic medication are viable treatment options.

First-Episode Schizophrenia Approaches Aided by Guidelines Instrument

First-Episode Schizophrenia Approaches Aided by Guidelines Instrument

By

Clinical practice guidelines are important resources for early intervention in a first episode of schizophrenia.

Art Therapy as an Intervention for Psychosis

Art Therapy as an Intervention for Psychosis

By

A patient does not have to be verbal to benefit from art therapy.

Schizophrenia Patient Dead After UTI Treatment

Schizophrenia Patient Dead After UTI Treatment

By

This case offers evidence of the interaction between ciprofloxacin and clozapine.

Mindfulness Intervention Effective for Distressing Voices in Psychosis

Mindfulness Intervention Effective for Distressing Voices in Psychosis

By

Combined cognitive therapy and mindfulness can have lasting positive effects on behavior and mood.

No Difference Between Omega-3 & Placebo in Patients at Ultrahigh Risk for Psychosis

No Difference Between Omega-3 & Placebo in Patients at Ultrahigh Risk for Psychosis

By

PUFA supplementation offers little additional aid to psychosis when good psychosocial care is already sought.

Prolactin-Related Symptoms Decrease with Reduced Risperidone Dosage

Prolactin-Related Symptoms Decrease with Reduced Risperidone Dosage

By

Hyperprolactinemia should be monitored during long-term risperidone treatment.

Psychiatric Care for Incarcerated Patients

Psychiatric Care for Incarcerated Patients

By

According to one review, there are more individuals with serious mental illness in correctional institutions than in all US state hospitals.

Efficacy of Lurasidone Assessed in Adolescents With Schizophrenia

Efficacy of Lurasidone Assessed in Adolescents With Schizophrenia

Sunovion have announced positive results from a study evaluating Latuda (lurasidone HCI) for the treatment of schizophrenia in adolescents aged 13 to 17 years old.

Impaired Auditory 40-Hz Steady-State Responses Noted in Schizophrenia

Impaired Auditory 40-Hz Steady-State Responses Noted in Schizophrenia

By

40-Hz ASSR spectral power and phase-locking deficits could be useful probes for assessing circuit dysfunctions in the disorder.

Prediabetic Markers May Be Linked With First-Episode Psychosis

Prediabetic Markers May Be Linked With First-Episode Psychosis

By

The findings might help to explain the increased prevalence of type 2 diabetes in patients with schizophrenia.

Significant Cognitive Impairment in Those At High Risk of Psychosis

Significant Cognitive Impairment in Those At High Risk of Psychosis

By

Studying cognition deficits during the clinical high risk period allows researchers to observe cognitive defects before chronicity and long-term medication use obscure the core deficits.

Study Elucidates Role of DIXDC1 Gene in Psychiatric Pathogenesis

Study Elucidates Role of DIXDC1 Gene in Psychiatric Pathogenesis

By

Dixdc1 knockout mice demonstrated behaviors suggestive of depression, anxiety, and impaired social behavior.

Psych Meds Rx May Reduce Violent Reoffending in Ex-Prisoners

Psych Meds Rx May Reduce Violent Reoffending in Ex-Prisoners

Medications used to treat addiction cut the risk of reoffending in half.

Heart Rate, BP in Male Teens Linked to Risk for Psych Disorders

Heart Rate, BP in Male Teens Linked to Risk for Psych Disorders

Indicators of schizophrenia, obsessive-compulsive disorder, and anxiety might be spotted in physical symptoms at age 18.

The Effect of Cognitive Remediation Training on Functional Connectivity and Social Cognition in Schizophrenia

The Effect of Cognitive Remediation Training on Functional Connectivity and Social Cognition in Schizophrenia

By

Study provides further evidence for the effects of cognitive enhancement intervention on brain functional connectivity and cognitive performance in patients with schizophrenia.

Gene Expression Patterns in Polygenic Schizophrenia Risk

Gene Expression Patterns in Polygenic Schizophrenia Risk

By

Data indicate that 693 genes are differentially expressed between individuals diagnosed with schizophrenia and typical, healthy controls.

Haloperidol in the Emergency Department Setting

Haloperidol in the Emergency Department Setting

By

Dr. Scott Zeller suggests it is time to move away from emergency intramuscular haloperidol.

Effort Allocation Influences Upon Cognition in Schizophrenia

Effort Allocation Influences Upon Cognition in Schizophrenia

By

Researchers studied social cognition and social problem solving in patients with schizophrenia by employing a validated test designed to assess emotion recognition abilities.

Delusions in Schizophrenia Associated With Myelin Abnormalities, Neuroinflammation

Delusions in Schizophrenia Associated With Myelin Abnormalities, Neuroinflammation

By

Study provides further evidence for the effects of white matter fiber abnormalities and neuroinflammation on positive symptoms in patients with schizophrenia.

White Matter Abnormalities and Clinical Symptom Severity in Schizophrenia

White Matter Abnormalities and Clinical Symptom Severity in Schizophrenia

By

New findings provide an insight about the association between white matter microstructure and the severity of schizophrenia clinical symptoms.

Interaction of Proline and COMT Genotype Influences Negative Symptoms in Schizophrenia & Bipolar Disorder

Interaction of Proline and COMT Genotype Influences Negative Symptoms in Schizophrenia & Bipolar Disorder

By

The authors explored whether valproate (VPA) treatment effects vary by catechol-O-methyltransferase (COMT) genotype.

Sign Up for Free e-newsletters